Title |
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
|
---|---|
Published in |
Journal of Hematology & Oncology, October 2013
|
DOI | 10.1186/1756-8722-6-81 |
Pubmed ID | |
Authors |
Moshe Talpaz, Ronald Paquette, Lawrence Afrin, Solomon I Hamburg, Josef T Prchal, Katarzyna Jamieson, Howard R Terebelo, Gregory L Ortega, Roger M Lyons, Ramon V Tiu, Elliott F Winton, Kavita Natrajan, Olatoyosi Odenike, David Claxton, Wei Peng, Peter O’Neill, Susan Erickson-Viitanen, Lance Leopold, Victor Sandor, Richard S Levy, Hagop M Kantarjian, Srdan Verstovsek |
Abstract |
Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume, symptoms, and survival over placebo and best available therapy in intermediate-2 or high-risk myelofibrosis patients with baseline platelet counts ≥100 × 109/L in phase III studies. The most common adverse events were dose-dependent anemia and thrombocytopenia, which were anticipated because thrombopoietin and erythropoietin signal through JAK2. These events were manageable, rarely leading to treatment discontinuation. Because approximately one-quarter of MF patients have platelet counts <100 × 109/L consequent to their disease, ruxolitinib was evaluated in this subset of patients using lower initial doses. Interim results of a phase II study of ruxolitinib in myelofibrosis patients with baseline platelet counts of 50-100 × 109/L are reported. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Denmark | 1 | 1% |
Peru | 1 | 1% |
Unknown | 65 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 18% |
Other | 8 | 12% |
Student > Master | 6 | 9% |
Student > Bachelor | 5 | 7% |
Student > Ph. D. Student | 5 | 7% |
Other | 8 | 12% |
Unknown | 23 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 24 | 36% |
Agricultural and Biological Sciences | 6 | 9% |
Biochemistry, Genetics and Molecular Biology | 4 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
Nursing and Health Professions | 1 | 1% |
Other | 4 | 6% |
Unknown | 25 | 37% |